In keeping with that, we previously observed a significant improvement (p = 0.008) of insulin sensitivity after 6 months of adalimumab therapy (QUICKI at baseline: 0.35 ± 0.04 versus 0.37 ± 0.04 at month 6) in our series of nondiabetic patients with moderate-to-severe psoriasis [8]. Here, INS is linked to psoriasis.